EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Open Access · CC BY 4.0

A phase I trial of autologous RAK cell immunotherapy in metastatic renal cell carcinoma

Jing Xu, Wen Zhang, Jinlian Tong, Caixia Liu, Qiaohui Zhang, Liren Cao, Jiangyong Yu, Aiping Zhou, Jie Ma

Cancer Immunology, Immunotherapy · 2024

DOI: 10.1007/s00262-024-03680-y ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Cancer Immunology, Immunotherapy, 2024. Verfasst von Jing Xu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Center of Biotherapy, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing…. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Kidney Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National High Level Hospital Clinical Research Funding, National Major Scientific and Technological Special Project for "Significant New Drugs Development", National Major Scientific and Technological Special Project for “Significant New Drugs Development”.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Treatment of metastatic renal cell carcinoma (mRCC) remains a challenge worldwide. Here, we introduced a phase I trial of autologous RAK cell therapy in patients with mRCC whose cancers progressed after prior systemic therapy. Although RAK cells have been used in clinic for many years, there has been no dose-escalation study to demonstrate its safety and efficacy.

Methods

We conducted a phase I trial with a 3 + 3 dose-escalation design to investigate the dose-related safety and efficacy of RAK cells in patients with mRCC whose cancers have failed to response to systemic therapy (ChiCTR1900021334).

Results

Autologous RAK cells, primarily composed of CD8 + T and NKT cells, were infused intravenously to patients at a dose of 5 × 10 9 , 1 × 10 10 or 1.5 × 10 10 cells every 28 days per cycle. Our study demonstrated general safety of RAK cells in a total of 12 patients. Four patients (33.3%) showed tumor shrinkage, two of them achieved durable partial responses. Peripheral blood analysis showed a significant increase in absolute counts of CD3 + and CD8 + T cells after infusion, with a greater fold change observed in naive CD8 + T cells (CD8 + CD45RA + ). Higher peak values of IL-2 and IFN- γ were observed in responders after RAK infusion.

Conclusion

This study suggests that autologous RAK cell immunotherapy is safe and has clinical activity in previously treated mRCC patients. The improvement in peripheral blood immune profiling after RAK cell infusion highlights its potential as a cancer treatment. Further investigation is necessary to understand its clinical utility.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Renal CellKidney NeoplasmsHumansCD8-Positive T-LymphocytesInterleukin-2ImmunotherapyAdjuvants, Immunologic

Stichwörter der Autor:innen

Autologous RAK cellEfficacyImmunotherapyMetastatic renal cell carcinomaSafety

Substanzen

Interleukin-2Adjuvants, Immunologic

Autor:innen und Institutionen

  • Center of Biotherapy, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, 100730, China.
  • Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, 100021, People's Republic…
  • Clinical Department, Everbright Cell Medical Biotech Inc., Beijing, 100061, People's Republic of China.
  • Department of Medical Oncology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, 100730, China.
  • Center of Biotherapy, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, 100730, China. majie4685@bjhmoh.cn.

Förderung

  • National High Level Hospital Clinical Research Funding
  • National Major Scientific and Technological Special Project for "Significant New Drugs Development"
  • National Major Scientific and Technological Special Project for “Significant New Drugs Development”

Zitieren

APA

Xu, J., Zhang, W., Tong, J., Liu, C., Zhang, Q., Cao, L., Yu, J., Zhou, A., & Ma, J. (2024). A phase I trial of autologous RAK cell immunotherapy in metastatic renal cell carcinoma. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-024-03680-y

Vancouver

Xu J, Zhang W, Tong J, Liu C, Zhang Q, Cao L, et al. A phase I trial of autologous RAK cell immunotherapy in metastatic renal cell carcinoma. Cancer Immunology, Immunotherapy. 2024. doi:10.1007/s00262-024-03680-y

BibTeX
@article{Xu2024,
  author = {Xu, Jing and Zhang, Wen and Tong, Jinlian and Liu, Caixia and Zhang, Qiaohui and Cao, Liren and Yu, Jiangyong and Zhou, Aiping and Ma, Jie},
  title = {A phase I trial of autologous RAK cell immunotherapy in metastatic renal cell carcinoma},
  journal = {Cancer Immunology, Immunotherapy},
  year = {2024},
  doi = {10.1007/s00262-024-03680-y}
}
Kostenlos starten →